Literature DB >> 23803742

The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B.

Roohangiz Safaei1, Preston L Adams, Ryan A Mathews, Gerald Manorek, Stephen B Howell.   

Abstract

The copper (Cu) exporter ATP7B mediates cellular resistance to cisplatin (cDDP) by increasing drug efflux. ATP7B binds and sequesters cDDP in into secretory vesicles. Upon cDDP exposure ATP7B traffics from the trans-Golgi network (TGN) to the periphery of the cell in a manner that requires the cysteine residues in its metal binding domains (MBD). To elucidate the role of the various domains of ATP7B in its cDDP-induced trafficking we expressed a series of mCherry-tagged variants of ATP7B in HEK293T cells and analyzed their subcellular localization in basal media and after a 1 h exposure to 30 μM cDDP. The wild type ATP7B and a variant in which the cysteines in the CXXC motifs of MBD 1-5 were converted to serines trafficked out of the trans-Golgi (TGN) when exposed to cDDP. Conversion of the cysteines in all 6 of the CXXC motifs to serines, or in only the sixth MBD, rendered ATP7B incapable of trafficking on exposure to cDDP. Truncation of MBD1-5 or MBD1-6 resulted in the loss of TGN localization. Addition of the first 63 amino acids of ATP7B to these variants restored TGN localization to a great extent and enabled the MBD1-5 variant to undergo cDDP-induced trafficking. A variant of ATP7B in which the aspartate 1027 residue in the phosphorylation domain was converted to glutamine localized to the TGN but was incapable of cDDP-induced trafficking. These results demonstrate that the CXXC motif in the sixth MBD and the catalytic activity of ATP7B are required for cDDP-induced trafficking as they are for Cu-induced redistribution of ATP7B; this provides further evidence that cDDP mimics Cu with respect to the molecular mechanisms by they control the subcellular distribution of ATP7B.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23803742      PMCID: PMC4030745          DOI: 10.1039/c3mt00131h

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  33 in total

1.  Metallochaperones and metal-transporting ATPases: a comparative analysis of sequences and structures.

Authors:  Fabio Arnesano; Lucia Banci; Ivano Bertini; Simone Ciofi-Baffoni; Elena Molteni; David L Huffman; Thomas V O'Halloran
Journal:  Genome Res       Date:  2002-02       Impact factor: 9.043

2.  Copper incorporation into ceruloplasmin is regulated by Niemann-Pick C1 protein.

Authors:  Chikatoshi Yanagimoto; Masaru Harada; Hiroto Kumemura; Mitsuhiko Abe; Hironori Koga; Masahiro Sakata; Takumi Kawaguchi; Kunihiko Terada; Shinichiro Hanada; Eitaro Taniguchi; Haruaki Ninomiya; Takato Ueno; Toshihiro Sugiyama; Michio Sata
Journal:  Hepatol Res       Date:  2011-05       Impact factor: 4.288

3.  Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper ATPase.

Authors:  S La Fontaine ; M B Theophilos; S D Firth; R Gould; R G Parton; J F Mercer
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

4.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors.

Authors:  P J DiSaia; J G Sinkovics; F N Rutledge; J P Smith
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

5.  Structure of human Wilson protein domains 5 and 6 and their interplay with domain 4 and the copper chaperone HAH1 in copper uptake.

Authors:  David Achila; Lucia Banci; Ivano Bertini; Jennifer Bunce; Simone Ciofi-Baffoni; David L Huffman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-29       Impact factor: 11.205

6.  The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin.

Authors:  Roohangiz Safaei; Preston L Adams; Mohammad H Maktabi; Ryan A Mathews; Stephen B Howell
Journal:  J Inorg Biochem       Date:  2012-03-03       Impact factor: 4.155

7.  The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.

Authors:  Christopher A Larson; Preston L Adams; Brian G Blair; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2010-06-02       Impact factor: 4.436

8.  Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.

Authors:  Alison K Holzer; Gerald H Manorek; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2006-07-17       Impact factor: 4.436

9.  Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin.

Authors:  Peter V E van den Berghe; Janneke M Stapelbroek; Elmar Krieger; Prim de Bie; Stan F J van de Graaf; Reinoud E A de Groot; Ellen van Beurden; Ellen Spijker; Roderick H J Houwen; Ruud Berger; Leo W J Klomp
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

10.  The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.

Authors:  Alison K Holzer; Goli Samimi; Kuniyuki Katano; Wiltrud Naerdemann; Xinjian Lin; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2004-06-30       Impact factor: 4.436

View more
  8 in total

Review 1.  Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.

Authors:  Helen H W Chen; Wen-Chung Chen; Zhang-Dong Liang; Wen-Bin Tsai; Yan Long; Isamu Aiba; Siqing Fu; Russell Broaddus; Jinsong Liu; Lynn G Feun; Niramol Savaraj; Macus Tien Kuo
Journal:  Expert Opin Ther Targets       Date:  2015-05-25       Impact factor: 6.902

2.  Human copper transporter ATP7B (Wilson disease protein) forms stable dimers in vitro and in cells.

Authors:  Samuel Jayakanthan; Lelita T Braiterman; Nesrin M Hasan; Vinzenz M Unger; Svetlana Lutsenko
Journal:  J Biol Chem       Date:  2017-08-24       Impact factor: 5.157

3.  Cisplatin inhibits MEK1/2.

Authors:  Tetsu Yamamoto; Igor F Tsigelny; Andreas W Götz; Stephen B Howell
Journal:  Oncotarget       Date:  2015-09-15

4.  ATP7B expression confers multidrug resistance through drug sequestration.

Authors:  F M Moinuddin; Yoshinari Shinsato; Masaharu Komatsu; Ryoichi Mitsuo; Kentaro Minami; Masatatsu Yamamoto; Kohich Kawahara; Hirofumi Hirano; Kazunori Arita; Tatsuhiko Furukawa
Journal:  Oncotarget       Date:  2016-04-19

Review 5.  The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets.

Authors:  Si Sun; Jing Cai; Qiang Yang; Simei Zhao; Zehua Wang
Journal:  Oncotarget       Date:  2017-02-28

Review 6.  Copper metabolism as a unique vulnerability in cancer.

Authors:  Vinit C Shanbhag; Nikita Gudekar; Kimberly Jasmer; Christos Papageorgiou; Kamal Singh; Michael J Petris
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-10-20       Impact factor: 4.739

Review 7.  miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition.

Authors:  Siti A Sulaiman; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2016-08-23       Impact factor: 5.810

Review 8.  Facilitating the Cellular Accumulation of Pt-Based Chemotherapeutic Drugs.

Authors:  Ian Henry Lambert; Belinda Halling Sørensen
Journal:  Int J Mol Sci       Date:  2018-08-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.